FibroScan®
Rethinking Metabolic Health in Everyday Primary Care
|
Primary care is where metabolic disease often first reveals itself—long before symptoms appear. Yet limited time, fragmented data, and imperfect tests can make early risk detection difficult. In this white paper, primary care physician Dr. Radhika Vayani, shares how integrating non-invasive liver assessment with FibroScan® into routine visits helps clinicians detect silent disease earlier, support shared care with specialists, and motivate patients with clear, objective data. Drawing from everyday practice, she outlines how FibroScan® enables more confident decision-making, stronger patient engagement, and a more proactive approach to metabolic health. |
 |
Key learnings
The Metabolic Reality in Primary Care
Metabolic dysfunction-associated steatotic liver disease (MASLD) is common, silent and closely linked to cardiometabolic disease.
Why Traditional Pathways Fall Short
Standard labs and ultrasounds may miss early disease.
Making Time Matter
Point-of-care evaluation with FibroScan® can fit seamlessly into routine visits.
Motivating Change with Visual Data
Quantifying steatosis and fibrosis helps patients understand risk and commit to change.
How to Risk Stratify & Refer with Confidence
Objective data from FibroScan® supports smarter management and referral decisions.
Download the white paper to see how early liver assessment can transform
how primary care practices can approach metabolic care